-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the proven effectiveness and safety of the Phase IIb clinical trial, OCS-01 is expected to become the first non-invasive topical eye drops for the treatment of diabetic macular edema (DME).
Hong Kong, November 16, 2021/PRNewswire/ - Oculis SA ("Oculis"), a biopharmaceutical company focused on clinical development and research, is pleased to announce that its Phase III clinical study called DIAMOND has completed the first batch of patient medications.
OCS-01 is a new type of high-concentration, preservative-free topical eye drops for dexamethasone (using dissolving nanoparticle formulation technology).
The Phase II clinical trial of OCS-01 obtained optimistic data and was announced for the first time at The Angiogenesis, Exudation, and Degeneration academic conference held in February 2020
DIAMOND is a double-blind, randomized, carrier-controlled, multi-center, multi-country OCS-01 Phase III clinical study for diabetic macular edema
Professor Ramin Tadayoni, MD, member of the Oculis Scientific Advisory Board, Director of the Department of Ophthalmology of the University of Paris, said: “Local eye drops are effective in the treatment of diabetic macular edema, which is of great significance to patients and can provide ophthalmologists with early treatment options
Dr.
Looking to the future, Oculis will achieve many milestone developments, and OCS-01, as one of our candidate new topical ophthalmic drops, has laid a solid first step
Last month, Oculis' Hong Kong office was formally established to enhance the company's future development and business capabilities in this important strategic region of China and Asia
About Diabetic Macular Edema (DME)*
Diabetic macular edema is the main cause of vision loss and blindness in diabetic patients, and 1 in 14 diabetic patients suffers from this disease
* Oculis
Oculis is a biopharmaceutical company headquartered in Lausanne, Switzerland, with operations in Europe, the United States and China, focusing on the development of new ophthalmic pharmaceutical preparations to improve the vision and life of patients
